Table 2.
Cancer | Selected evidence for DKK1 cancer‐promoting activity | Reference |
---|---|---|
Breast |
|
(Voorzanger‐Rousselot et al., 2007; Smadja et al., 2010; Malladi et al., 2016) |
Cholangiocarcinoma |
|
(Shi et al., 2013; Shi et al., 2016) |
Colorectal |
|
(Aguilera et al., 2015) |
Oesophageal |
|
(Li et al., 2011) |
Liver |
|
(Yu et al., 2009; Tung et al., 2011; Chen et al., 2013; Tao et al., 2013; Huang et al., 2014; Kim et al., 2015; Chen et al., 2016) |
Laryngeal |
|
(Shi et al., 2014) |
Lung |
|
(Sato et al., 2010; Li et al., 2013; Salim et al., 2015; D'Amico et al., 2016; Kimura et al., 2016; Malladi et al., 2016; Yao et al., 2016; Pang et al., 2017) |
Melanoma |
|
(D'Amico et al., 2016) |
MFH |
|
(Matushansky et al., 2007) |
Multiple myeloma |
|
(Yaccoby et al., 2007; Fulciniti et al., 2009; Heath et al., 2009; Pozzi et al., 2013) |
Osteosarcoma |
|
(Gregory et al., 2003; Krause et al., 2014; Goldstein et al., 2016) |
Ovarian |
|
(Wang and Zhang, 2011) |
Pancreatic |
|
(Takahashi et al., 2010; Kimura et al., 2016) |
Prostate |
|
(Hall et al., 2010; Thudi et al., 2011) |
MFH, malignant fibrous histiocytoma; hMSCs, human mesenchymal stem cells; PDX, patient‐derived xenograft.